Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar\u00ae for Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Verity Pharmaceuticals Reports that Bladder Cancer Drug Shortage Resolved with Health Canada Approval","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Acerus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO\u00ae in Puerto Rico","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Cumberland Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso\u00ae","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Lipocine","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"$2.5 million","newsHeadline":"Lipocine and Verity Pharma Enter into License Agreement for TLANDO\u00ae Franchise in the U.S. and Canada","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Verity Pharmaceuticals Inc","sponsor":"Lipocine","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"$2.5 million","newsHeadline":"Lipocine Announces Continued Commercialization of TLANDO\u00ae Through Verity Pharmaceuticals","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Verity Pharmaceuticals Inc

    Menu

    Verity Pharmaceuticals Inc

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Verity Pharmaceuticals Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lipocine Announces Continued Commercialization of TLANDO® Through Verity Pharmaceuticals

              Details:

              Verity will market TLANDO (testosterone undecanoate), the first and only oral testosterone replacement therapy in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone, in the United States and, if approved, in Canada.

              Lead Product(s): Testosterone Undecanoate

              Therapeutic Area: Endocrinology Product Name: Tlando

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Lipocine

              Deal Size: $270.0 million Upfront Cash: $2.5 million

              Deal Type: Licensing Agreement February 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verity Pharmaceuticals Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

              Details:

              Under the agreement, Verity Pharma will market Tlando (testosterone undecanoate), the first and only oral testosterone replacement therapy (TRT), in the United States and, if approved, in Canada.

              Lead Product(s): Testosterone Undecanoate

              Therapeutic Area: Endocrinology Product Name: Tlando

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Lipocine

              Deal Size: $270.0 million Upfront Cash: $2.5 million

              Deal Type: Licensing Agreement January 18, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verity Pharmaceuticals Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®

              Details:

              Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.

              Lead Product(s): Granisetron

              Therapeutic Area: Gastroenterology Product Name: Sancuso

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Cumberland Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verity Pharmaceuticals Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for the Promotion of NATESTO® in Puerto Rico

              Details:

              Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activities on the island of Puerto Rico.

              Lead Product(s): Testosterone

              Therapeutic Area: Endocrinology Product Name: Natesto

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Acerus Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 10, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verity Pharmaceuticals Inc

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Verity Pharmaceuticals Reports that Bladder Cancer Drug Shortage Resolved with Health Canada Approval

              Details:

              Verity Pharmaceuticals has received a notice of compliance with conditions (NOC/c) from Health Canada for the VERITY-BCG™ (Bacillus Calmette-Guérin [BCG]: Strain Russian BCG-I).

              Lead Product(s): Bacillus Calmette-Guérin: Strain Russian BCG-I

              Therapeutic Area: Oncology Product Name: VERITY-BCG

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Verity Pharmaceuticals Inc

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer

              Details:

              The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.

              Lead Product(s): Triptorelin Pamoate

              Therapeutic Area: Oncology Product Name: Trelstar

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Debiopharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY